Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Iovance Biotherapeutics is unwinding some of last week's squeeze gains, with the stock down 10% on the week to $12.96, and short sellers who survived the guidance-driven surge now seeing the first meaningful relief in months.
The story has changed materially since last week's note. That article documented the positioning paradox: bears holding 20% of float through a 36% squeeze, deeply underwater, with no sign of covering. This week the picture shifts. Short interest has fallen to 19.2% of the free float, roughly 76.1 million shares, down 6% over the past five days. That is the most aggressive week of covering since the early September episode when bears were building. The stock is still up 47% over the past month, so anyone who held short through the guidance catalyst and is now covering is crystallising substantial losses. The question is whether this week's modest covering represents the start of a longer unwind or merely the edges of the position being trimmed.
The lending market tells a consistent story: there is no squeeze pressure. Availability has expanded to 328%, meaning more than three shares are available to borrow for every one already lent out. That is well above the 52-week tightest level of 10%, and the trend has been loosening consistently since the short-interest peak in early September, when availability was far more constrained. Cost to borrow, while up 57% on the week, remains low in absolute terms at 0.50%. The weekly spike in borrowing cost looks like noise against a baseline that has barely moved in months. Options positioning has edged more defensive. The put/call ratio is 0.53, around 1.5 standard deviations above its 20-day average of 0.47, and close to the 52-week high of 0.58. That is not an extreme reading, but it has drifted higher every day this week, consistent with some hedging ahead of November 6 earnings.
The Street has moved aggressively in IOVA's favour over the past two weeks, and the collective uplift in price targets is notable. Wells Fargo raised its target to $18 while maintaining Overweight. Goldman Sachs reinstated coverage with a Buy and a $15 target on September 24. Barclays lifted to $15. HC Wainwright moved its target to $20. Against a current price of $12.96, the mean analyst target of $12.80 looks almost exactly flat, which flags a disconnect: the cluster of recent upgrades are all sitting materially above that mean, suggesting older, lower targets from before the guidance raise are dragging the average down. The analyst recommendation divergence factor score ranks in the 92nd percentile, reflecting a lopsided bull consensus. The bear case remains focused on competitive pressure from approved melanoma agents and emerging CAR-T therapies in solid tumours, along with financing risk and binary clinical outcomes in NSCLC.
Ownership flows add context. BlackRock added 5.9 million shares in its most recently reported period and now holds 8.2% of shares outstanding. State Street added 7 million shares and crossed 5.4%. Both disclosures carry the standard caveat that 13D/G stakes are as-last-reported around the 5% threshold. The short score has eased from 66.5 on September 28 to 62.3 today, a meaningful move lower in a measure that aggregates short-side pressure. Wikipedia attention, a retail-interest signal tracked by ORTEX Alt Data via the Wikimedia Foundation, registered a z-score of 3.1 relative to the stock's own 90-day history through September 30, consistent with elevated retail engagement following the guidance announcement. That dataset is not measured to lead the company's financials, but the attention spike aligns with the surge and the subsequent volatility.
The next hard event is Q3 earnings on November 6, thirty days away. The single comparable earnings reaction in the data shows the stock moved 46% on the day and 50% over the following five days after the August 6 result, which was the quarter carrying the guidance raise. With availability loose, short interest still at 19%, and the put/call ratio drifting higher, the setup into that print will be the defining question for positioning over the next month.
See the live data behind this article on ORTEX.
Open IOVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
